Clinical trials to test the ability of the intravenous administration of eIF4E-specific antisense oligonucleotides, that are therapeutic to treating human cancers has begun. Recently we posted on this research conducted on mice by Jeremy Graff and colleagues from Eli Lilly. This is a huge leap of discovery, and we most certainly hope that it has positive results.
The ability to knock out cancer without affecting perfectly healthy surrounding tissues is possibly just around the corner. To know that for some cancers we may not have to go through the radiation therapy, or the sickness of losing so many of our good cells while trying to conquer the bad ones is "hope".
Read more at Science Daily
Recommended reading by:
XLPharmacy Canada
